NanoViricides, Inc. (NYSE American: NNVC) has announced that it has received regulatory approval from the local regulatory agency ACOREP in the Democratic Republic of Congo (DRC) to initiate a Phase II clinical trial of NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with initial trial preparations already underway to accelerate first patient dosing. Sufficient quantities of NV-387 Oral Gummies to begin the trial are already in the DRC, according to the company.
NV-387 is an investigational broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The oral formulation could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusion. The company cited World Health Organization data showing 4,141 confirmed cases and 1,889 confirmed deaths from the current Bundibugyo ebolavirus outbreak in the DRC as of Aug. 6, 2026. This approval marks a critical step in addressing a deadly outbreak that has strained local healthcare infrastructure.
The importance of this development lies in the potential for an oral antiviral to be deployed more easily in remote and resource-limited areas, where intravenous treatments are often impractical. Current Ebola treatments, such as monoclonal antibodies, require cold chain logistics and trained medical personnel for administration. An oral gummy formulation could simplify distribution and administration, enabling broader access to treatment and potentially reducing mortality rates. Moreover, NV-387's broad-spectrum activity suggests it could be effective against multiple Ebola virus species, including the Bundibugyo strain, which has historically caused severe outbreaks.
This Phase II trial will provide crucial data on the safety and efficacy of NV-387 in humans. If successful, it could lead to a new therapeutic option for Ebola, complementing existing vaccines and treatments. The approval also highlights the importance of international collaboration in responding to emerging infectious disease threats. NanoViricides' ability to rapidly mobilize trial supplies to the DRC demonstrates a commitment to addressing urgent public health needs.
The company's lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID-19, Long COVID, Influenza, and MPOX. This broad-spectrum approach could position NanoViricides as a key player in pandemic preparedness. However, as with all drug development, there are significant risks and uncertainties. The company cautions that there is no assurance that NV-387 will demonstrate sufficient effectiveness and safety in clinical trials to gain regulatory approval.
The initiation of this trial in the DRC underscores the urgent need for effective treatments in outbreak settings and could pave the way for future studies in other affected regions. The results of this trial will be closely watched by the global health community, as they could inform strategies for managing Ebola outbreaks and improving patient outcomes. For more information on NanoViricides and its pipeline, visit https://www.nanoviricides.com.
